朱红艳-yb体育官方

作者:金飞     日期:2023-10-11   点击数:2476  

师资介绍


姓名:朱红艳

性别:女

民族:汉族

出生年月:1978.06.23

职称:教授

学历:博士

职务:药物制剂系党支部书记

                          

研究方向:1.核酸药物递释系统;2.仿生药物递送系统。

主持或参加科研项目(课题)

1.      江苏省自然科学基金面上项目,bk20201443,靶向调控肿瘤转移前微环境的工程化“外泌体影”仿生递释系统研究,2020/7-2023/610万元,在研,主持 

2.      国家自然科学基金青年基金项目,81202467,胞内触发释药的仿生型sirna自组装胶束纳米复合物的构建、抗肿瘤转移作用及细胞内药物动力学研究,2013/1-2015/1223万元,已结题,主持 

3.      江苏省青年科学基金项目bk2012232靶向肿瘤血管生成的仿生型小核酸药物递释系统研究20万元,已结题,主持 

4.      江苏省教育厅高校自然科学研究面上项目11kjb350004谷胱甘肽触发释放的智能型sirna复合载体(穿膜肽tat-壳聚糖-量子点)的构建及其抗肿瘤活性研究3万元,已结题,主持 

5.      江苏省高校自然科学研究指导性项目06kjd310150南瓜多糖对链脲菌素诱导的胰岛损伤的保护作用及机制研究,2007/01-2008/121万元,已结题,主持。

6.      南通市课题,exosome@cbsa 仿生 sirna 递送系统的构建及其抗乳腺癌术后转移作用研究,2018.07-2020.06,项目编号:jc20180245万元。

代表性研究成果和学术奖励情况

第一作者和通讯作者论文,专利

(2)            haiqin huang, lanlan shao, yan chen, weili han, yao zhou, tianqing liu, jinhua gu,* and hongyan zhu*. sequential dual delivery system based on sicox-2-loaded gold nanostar and thermal-sensitive liposomes overcome hypoxia mediated multidrug resistance in tumors. mol. pharmaceutics. 2022, 19(7):2390-2405.

(3)              yongmei zhao, yuanlin zheng, yan zhu, hongyun li, hongyan zhu* and tianqing liu*. docetaxel-loaded m1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer. journal of nanobiotechnology. 2022, 20:359.

(4)          haiqin huang, lanlan shao, yan chen, lan tang, tianqing liu, junxu li, and hongyan zhu*. synergistic strategy with hyperthermia therapy based immunotherapy and engineered exosomes liposomes targeted chemotherapy prevents tumor recurrence and metastasis in advanced breast cancer. bioeng transl med. 2021, 7(2):e10284.

(5)                 shengyu zhang, ye gan, lanlan shao, tianqing liu, danyi wei, yanyan yu,* hongwei guo,* and hongyan zhu*. virus mimetic shell-sheddable chitosan micelles for sivegf delivery and fret-traceable acid-triggered release. acs appl. mater. interfaces. 2020, 12, 53598−53614.if=9.229

(6)              liuwan zhao, chunyan gu, ye gan, lanlan shao, hongwei chen, hongyan zhu*. exosome-mediated sirna delivery to suppress postoperative breast cancer metastasis. j control release. 2020, 318, 1-15.if=9.776

(7)                  ,, , , , , * and *. combined modality therapy based on hybrid gold nanostars coated with temperature sensitive liposomes to overcome paclitaxel-resistance in hepatic carcinoma. pharmaceutics 2019, 11(12), 683if=6.321

(8)                 yanyan yu, min zhou, wei zhang, lei huang, dandan miao, hongyan zhu*, gaoxing su*. rattle-type gold nanorods/porous-sio2 nanocomposites as near-infrared light-activated drug delivery systems for cancer combined chemo-photothermal therapy. mol. pharmaceutics. 2019,16(5) 1929-1938if=4.939

(9)                   *. mesoporous silica-coated gold nanostars with drug payload for combined chemo-photothermal cancer therapy.  2019 feb; 27(2):201-210. if=5.121

(10)                shengyu , yanjun , ye , nanqing , yueqing hongyan zhu*. conjugates of tat and folate with dox-loaded chitosan micelles offer effective intracellular delivery ability.  2019, 24(2):253-261.if=3.133

(11)                shengyu zhang, liuwan zhao, nanqin qiu, yanjun liu, bohui xu, hongyan zhu*, on the hypoxic tumor targeting ability of two chitosan micelles loaded with oil-soluble cdse quantum dots.  2018, 23(1):87-95.if=3.133

(12)                 hongyan zhu*, wanwan liu, ziting cheng, ke yao, yu yang, bohui xu and gaoxing su*, targeted delivery of sirna with ph-responsive hybrid gold nanostars for cancer treatment.  2017, 18(10):2029.if=5.923

(13)               fei liu, yuan sun, chen kang, hongyan zhu*. pegylated drug delivery systems: from design to biomedical applications. nano life. 2016, 6(3, 4):1642002 (1-11).

(14)             bohui xu, yubin wang, hongyan zhu*. mini-tablet combination for sustained release of clonidine hydrochloride and hydrochlorothiazide: preparation and pharmacokinetics in beagle dogs. pharmazie. 2016 71(2):76-83. if=1.267

(15)                hongyan zhu, shengyu zhang, yongling, guoliang meng, yu yang, wei zhang*.  j control release. 2015, 220(pt a):529-544. if=9.776

(16)                 hongyan zhu, guangtong chen, guoliang meng jiliang xu*. characterization of pumpkin polysaccharides and protective effects on streptozotocin-damaged islet cells. chin j nat med. 2015, 13(3):199-207. if=3.000

(17)                 hongyan zhu, jingping zhu, aimei xie, yong lin, beibei zhang, yifei wang, wei zhang*.visible quantum-dot-based targeted sirna delivery for hif-1α gene silencing. j. drug del. sci. tech. 2014, 24 (5): 445-451.if=3.981

(18)        hongyan zhu, jie cao, sisi cui, zhiyu qian, yueqing gu*. enhanced tumor targeting and antitumor efficacy via hydroxycamptothecin-encapsulated folate-modified n-succinyl-n-octyl chitosan micelles. j pharm sci. 2013, 102 (4):1318-1332. if=3.534

(19)                 hongyan zhu, fei liu, jing guo, jianpeng xue, zhiyu qian, yueqing gu*. folate-modified chitosan micelles with enhanced tumor targeting evaluated by near infrared imaging system. carbohydrate polymers. 2011, 86(3):1118-1129. if=9.381

(20)                 jie cao#, hongyan zhu#, dawei deng, bing xue, liping tang, didel mahounga, zhiyu qian, yueqing gu*, in vivo nir imaging with pbs quantum dots entrapped in biodegradable micelles. journal of biomedical materials research part a. 2012: 100a: 958-968. if=4.396

(21)                 程紫婷,姚珂,刘婉婉,许伯慧,朱红艳*, 紫杉醇温敏脂质体与sirna金纳米星载药系统的构建与表征. 中国药科大学学报. 2017, 48(4):444-45.

(22)                 朱红艳,  朱景平,  谢爱梅,  袁静,  花烨,  张伟*. 肿瘤靶向高分子碲化镉量子点复合纳米粒的制备及其表征. 药学学报. 2014, 49 (10): 1457 -1465.

(23)                 刘婉婉,张胜喻,杨彧,朱红艳*. 具有肿瘤靶向及穿膜效应的壳聚糖胶束的制备. 中国药科大学学报. 2015, 46(5): 561-567.

(24)                 周瑶,曹欣雨,周佳敏,朱红艳*. 口服维生素c脂质体的制备及其稳定性研究. 南通大学学报(医学版). 2020, 40(5): 1-3.

(25)                 发明专利:朱红艳, 许伯慧, 陈忠平. 一种仿生sirna胶束纳米复合物及应用. 专利号:zl 2015 1 0189351.6,授权日:2018.07.24.

(26)                 朱红艳,赵刘碗,韩伟莉. sirna纳米载体及其制备方法和应用. 专利号:

(27)                 已经转让的专利:朱红艳, 谢爱梅, 杨池, 张贝贝, 王逸飞. 一种基于量子点的多功能纳米sirna载体系统的制备及应用. 专利号:zl 2014 1 0087972.9,转让时间:2020年,转让经费:4万元。

(28)                 朱红艳,赵刘碗, 韩伟莉. 光热材料和外泌体介导的化疗药组成的药物及其用途. 申请号:2019101129258, 实审发文号:2019042800173150.


网站地图